

Edgar Filing: ICN PHARMACEUTICALS INC - Form DEFA14A

ICN PHARMACEUTICALS INC  
Form DEFA14A  
May 17, 2001

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant To Section 14(a) Of  
The Securities Exchange Act Of 1934

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY  
RULE 14A-6(E)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to Section 240.14a-12

ICN Pharmaceuticals, Inc.

-----  
(Name of Registrant as Specified in its Charter)

N/A

-----  
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

(1) Title of each class of securities to which transaction applies:  
-----

(2) Aggregate number of securities to which transaction applies:  
-----

(4) Proposed maximum aggregate value of transaction:  
-----

(5) Total fee paid:  
-----

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act  
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was  
paid previously. Identify the previous filing by registration statement  
number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:  
-----

(2) Form, Schedule or Registration Statement No.:  
-----

(3) Filing Party:  
-----

(4) Date Filed:  
-----

Following is the text of a press release issued on May 17, 2001:

[LOGO - ICN]  
-----

ICN PHARMACEUTICALS, INC.

Edgar Filing: ICN PHARMACEUTICALS INC - Form DEFA14A

International Headquarters  
ICN Plaza  
3300 Hyland Avenue  
Costa Mesa, California 92626

Telephone: (714) 545-0100 x3230  
FAX: (714) 641-7215  
Telex: 67-0413

Investors:  
-----  
Joe Schepers  
212-754-4422

Media:  
-----  
Peter Murphy  
714-545-0100, ext. 3213

ICN PHARMACEUTICALS LAUNCHES ANNUAL MEETING WEB PAGE

COSTA MESA, Calif., May 17, 2001 -- ICN Pharmaceuticals, Inc. (NYSE: ICN), a research-based global pharmaceutical company, today announced that it has established a new web page to host information for the Company's 2001 annual shareholders meeting.

The web page contains recent news releases relating to the Company's current restructuring status, corporate advertisements highlighting the Company's performance, a comprehensive proxy statement detailing background information on the Company's current nominees for the Board of Directors.

Two of the current nominees have a pre-recorded video streaming presentation on the web page. The nominees include: Dr. Ray Irani, Chairman and CEO of Occidental Petroleum and The Right Honorable Kim Campbell, former Prime Minister of Canada. There is also a special shareholder message by Chairman and CEO Milan Panic.

You may view this web page at [www.icnpharm.com](http://www.icnpharm.com), [www.icnannualmeeting.com](http://www.icnannualmeeting.com) and [www.icnproxy.com](http://www.icnproxy.com).

ICN is an innovative, research-based, global pharmaceutical company that manufactures markets and distributes a broad range of prescription and non-prescription pharmaceuticals under the ICN brand name. Its therapeutic focus is on anti-infectives, including anti-virals, dermatology and oncology. Additional information is also available on the company's website at <http://www.icnpharm.com>.

THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. This press release contains forward-looking statements that involve risks and uncertainties, including but not limited to, projections of future sales, operating income, returns on invested assets, regulatory approval processes, and other risks detailed from time to time in the Company's Securities and Exchange Commission filings.

###